FI96210B - Kromatografisk avskiljning av plasmaproteiner - Google Patents
Kromatografisk avskiljning av plasmaproteiner Download PDFInfo
- Publication number
- FI96210B FI96210B FI900397A FI900397A FI96210B FI 96210 B FI96210 B FI 96210B FI 900397 A FI900397 A FI 900397A FI 900397 A FI900397 A FI 900397A FI 96210 B FI96210 B FI 96210B
- Authority
- FI
- Finland
- Prior art keywords
- factor
- chromatography
- fibronectin
- proteins
- factor viii
- Prior art date
Links
- 238000013375 chromatographic separation Methods 0.000 title claims description 6
- 102000004506 Blood Proteins Human genes 0.000 title description 5
- 108010017384 Blood Proteins Proteins 0.000 title description 5
- 229960000301 factor viii Drugs 0.000 claims abstract description 38
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 37
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 34
- 229960001134 von willebrand factor Drugs 0.000 claims abstract description 27
- 239000012141 concentrate Substances 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 21
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 20
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 20
- 239000000872 buffer Substances 0.000 claims abstract description 20
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 19
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 5
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 24
- 102100036537 von Willebrand factor Human genes 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000535 fibrinogen concentrate Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims 4
- 238000005349 anion exchange Methods 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 108010033683 von Willebrand factor drug combination factor VIII Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 abstract description 17
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract description 4
- 230000003993 interaction Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000011210 chromatographic step Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003364 biologic glue Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Förfarande för separation av plasmaproteinerna fibrinogen, fibronektin, von Willebrands faktor och faktor
2. Förfarande enligt patentkrav 1, kanne- t e c k n a t därav, att gelen av vinylpolymertyp är Fractogel -TSK. 30
3. Förfarande enligt patentkrav 1 eller 2, k ä n - netecknat därav, att utgängsfraktionen innehäller faktor VIII, vilkens specifikä aktivitet överstiger eller är lika med 0,1 IU/mg protein.
4. Förfarande enligt nägot av patentkraven 1-3, 35 kännetecknat därav, att utgängsfraktionen har 96210 undergätt en reningsförbehandling som omfattar - behandling med aluminiumhydroxid - avkylning tili 14 - 16 °C , - centrifugering och tillvaratagande av supernatan- 5 ten.
5. Förfarande enligt nägot av patentkraven 1-4, kännetecknat därav, att kromatografin utförs med en buffert innehällande lysin och glycin, vilkens jon-styrka ökas med ökande koncentrationer av natriumklorid. 10
6. Förfarande enligt patentkrav 5, känne tecknat därav, att bufferten innehäller 2-4 g/1 lysin och 8-11 g/1 glycin.
5 VIII av humant eller animalt ursprung och för framställ-ning av koncentrat av dessa proteiner, känneteck-n a t därav, att man som utgängsmaterial använder en plasmakryopre-cipitatsfraktion väsentligen bestäende av nämnda protei-10 ner, det i en vattenhaltig lösning lösta kryoprecipita-tet utsätts för en enda separation medelst kromatografi pä ett anjonbytarharts vars anjonbytaregenskaper beror pä grupper av DEAE-typ, vilka bundits tili en gelmatris av 15 makroretikulärvinylpolymertyp som pä grund av sinä hydro-foba och porösa egenskaper förmär adsorbera ett faktor VIII-von Willebrands faktor -komplex, och de enskilda proteinerna utvinns selektivt genom att . öka elueringsbuffertens jonstyrka, varvid, dä man använder 20 natriumklorid, buffertens natriumkloridkoncentration i början är 0,11 M, vilket möjliggör adsorption av fibronektin, von Willebrands faktor och faktor VIII och tilläter passage av fibrinogen i eluatet, höjs tili 0,15 M för eluering av fibronektin och den största delen av von Wil-25 lebrands faktor och höjs tili 0,25 M för eluering av faktor VIII.
7. Förfarande enligt nägot av patentkraven 1-6, kännetecknat därav, att plasmafraktionen ut- 15 sätts för en virusinaktiverande behandling i närvaro av kemiska, inaktiverande medel omedelbart före det kromato-grafiska separationssteget.
8. Förfarande enligt nägot av patentkraven 1-7, . kännetecknat därav, att eluatet frän kromato- 20 grafin tillvaratas och kromatograferas pä ett heparin-Se-pharose -harts för tillvaratagande av ett fibrinogenkon-centrat.
9. Förfarande enligt nägot av patentkraven 1-7, kännetecknat därav, att ett första eluat till- 25 varatas frän kromatografin och leds genom en andra kolonn, som är likadan som den första kolonnen med samma buffert, vilken inställts tili 0,15 M i förhällande tili NaCl för tillvaratagande av ett koncentrat av von Willebrands fak-tor. ' 30
10. Förfarande enligt nägot av patentkraven 1 - 7, kännetecknat därav, att ett första eluat tillvaratas frän kromatografin och utsätts för molekylsällkro-matografi för tillvaratagande av ett fibronektinkoncen-trat.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8807530 | 1988-06-07 | ||
FR8807530A FR2632309B1 (fr) | 1988-06-07 | 1988-06-07 | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
PCT/FR1989/000050 WO1989012065A1 (fr) | 1988-06-07 | 1989-02-08 | Separation chromatographique des proteines du plasma |
FR8900050 | 1989-02-08 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI900397A0 FI900397A0 (sv) | 1990-01-25 |
FI96210B true FI96210B (sv) | 1996-02-15 |
FI96210C FI96210C (sv) | 1996-05-27 |
Family
ID=9367001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI900397A FI96210C (sv) | 1988-06-07 | 1990-01-25 | Kromatografisk avskiljning av plasmaproteiner |
Country Status (17)
Country | Link |
---|---|
US (1) | US5252709A (sv) |
EP (1) | EP0359593B2 (sv) |
JP (1) | JP2805364B2 (sv) |
KR (1) | KR970010923B1 (sv) |
AT (1) | ATE121750T1 (sv) |
AU (2) | AU622436B2 (sv) |
CA (1) | CA1340742C (sv) |
DE (2) | DE68922358T3 (sv) |
DK (1) | DK175322B1 (sv) |
ES (1) | ES2070919T5 (sv) |
FI (1) | FI96210C (sv) |
FR (1) | FR2632309B1 (sv) |
LT (1) | LT3333B (sv) |
NO (1) | NO177188C (sv) |
RU (1) | RU1837880C (sv) |
UA (1) | UA11061A (sv) |
WO (1) | WO1989012065A1 (sv) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8729822D0 (en) * | 1987-12-22 | 1988-02-03 | Central Blood Lab Authority | Chemical process |
DE3904354A1 (de) * | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
FR2644064B1 (fr) * | 1989-02-17 | 1994-05-27 | Aquitaine Dev Transf Sanguine | Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant |
FR2665449B1 (fr) * | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
US5760183A (en) * | 1989-02-17 | 1998-06-02 | Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques | Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same |
DE3926034C3 (de) * | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Verfahren zur Herstellung eines stabilen Faktors VIII |
FR2651437A1 (fr) * | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
NL9000090A (nl) * | 1990-01-15 | 1991-08-01 | Harimex Ligos Bv | Werkwijze voor het bereiden van een fibrinogeenconcentraat uit bloedplasma, inrichting voor het uitvoeren van deze werkwijze en werkwijze voor het bereiden van fibrinogeen uit het concentraat. |
FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
FR2681867B1 (fr) * | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | Procede de purification du facteur viii et preparations obtenues. |
DE4202667C1 (sv) * | 1992-01-29 | 1993-05-13 | Behringwerke Ag, 3550 Marburg, De | |
DE4204694C3 (de) * | 1992-02-01 | 1995-10-12 | Octapharma Ag | Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie |
FR2686883B1 (fr) * | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
AT399818B (de) * | 1992-04-24 | 1995-07-25 | Immuno Ag | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation |
CA2195127C (en) † | 1994-07-14 | 2007-06-19 | Ruth Laub | Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation |
DE4435485C1 (de) * | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
EP0910581B1 (de) * | 1996-06-24 | 2000-04-05 | Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH | Verfahren zur affinitätschromatographischen aufreinigung von faktor viii |
US6037457A (en) * | 1997-01-31 | 2000-03-14 | The University Of North Carolina At Chapel Hill | Method for recombinant fibrinogen production |
AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
RU2244556C2 (ru) | 1999-02-22 | 2005-01-20 | Юниверсити Оф Коннектикут | Новые не содержащие альбумин составы фактора viii |
EP1148063A1 (de) * | 2000-04-18 | 2001-10-24 | Octapharma AG | Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung |
FR2857267B1 (fr) | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
EP2821135A1 (en) * | 2004-02-05 | 2015-01-07 | EMD Millipore Corporation | Porous adsorptive or chromatographic media |
DE102004009400A1 (de) | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
FR2874216B1 (fr) | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
FR2885369B1 (fr) * | 2005-05-04 | 2010-11-12 | Lab Francais Du Fractionnement | Materiel infectieux synthetique et standardise de type prion et ses utilisations en tant qu'inoculum infectant. |
FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
US9433922B2 (en) * | 2007-08-14 | 2016-09-06 | Emd Millipore Corporation | Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same |
FR2920429B1 (fr) * | 2007-08-30 | 2012-10-05 | Lfb Biotechnologies | Procede de purification du facteur viii et du facteur von willebrand |
US20090130738A1 (en) * | 2007-11-19 | 2009-05-21 | Mikhail Kozlov | Media for membrane ion exchange chromatography |
US20110065900A1 (en) * | 2008-05-30 | 2011-03-17 | Ge Healthcare Bio-Science Ab | Separation method utilizing polyallylamine ligands |
EP2293776B8 (de) | 2008-06-23 | 2016-05-11 | Bio-Products & Bio-Engineering Aktiengesellschaft | Lagerstabiles, funktionell intaktes virus-inaktiviertes fibrinogen |
JP5779780B2 (ja) | 2008-11-07 | 2015-09-16 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 第viii因子製剤 |
IT1396528B1 (it) * | 2009-01-19 | 2012-12-14 | Kedrion Spa | Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn). |
EP2499165B1 (en) | 2009-11-13 | 2016-09-14 | Grifols Therapeutics Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
FR2952641B1 (fr) | 2009-11-18 | 2012-01-13 | Lfb Biomedicaments | Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion |
WO2011086197A1 (en) | 2010-01-18 | 2011-07-21 | Novo Nordisk Health Care Ag | Purification of blood coagulation factors |
RU2445974C2 (ru) * | 2010-04-26 | 2012-03-27 | Учреждение Российской академии медицинских наук Гематологический научный центр ГНЦ РАМН | Способ получения концентрата фактора viii из плазмы крови человека |
US9488625B2 (en) | 2010-12-15 | 2016-11-08 | Baxalta GmbH | Purification of factor VIII using a conductivity gradient |
US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
US20140154233A1 (en) * | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
FR3034669B1 (fr) | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
WO2019050321A1 (ko) * | 2017-09-07 | 2019-03-14 | (주)프로테옴텍 | 다수의 검사선을 구비한 크로마토그래피용 스트립, 이를 포함하는 진단 키트 및 다수의 경쟁적 반응 측정 단계를 포함하는 정성, 반정량, 정량 분석방법 |
EP3488858A1 (en) | 2017-11-27 | 2019-05-29 | Laboratoire Français du Fractionnement et des Biotechnologies | A von willebrand factor composition for use in treating a pathology mediated by angiogenesis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4278594A (en) * | 1979-06-19 | 1981-07-14 | David Amrani | Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma |
EP0022053A1 (en) * | 1979-06-25 | 1981-01-07 | Rexnord Inc. | Shear bar having notched edge configuration |
US4341764A (en) * | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
US4361509A (en) * | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4508709A (en) * | 1983-12-05 | 1985-04-02 | Armour Pharmaceutical Company | Process for purifying factor VIII:C |
GB8403473D0 (en) * | 1984-02-09 | 1984-03-14 | Special Trustees For St Thomas | Purification of factor viii |
FR2570276B1 (fr) * | 1984-09-18 | 1987-09-04 | Immunotech Sa | Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant |
US4543210A (en) * | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
US4743680A (en) * | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
JPS61189228A (ja) * | 1985-02-19 | 1986-08-22 | Nippon Sekijiyuujishiya | 血液凝固第8因子製剤の製法 |
EP0235526A3 (de) * | 1986-01-29 | 1988-03-23 | Leipziger Arzneimittelwerk GmbH | Aktivierte Polymerfestkörper und Verfahren zu ihrer Herstellung |
DE3609431A1 (de) * | 1986-03-20 | 1987-09-24 | Biotest Pharma Gmbh | Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates |
DE3707213A1 (de) * | 1987-03-06 | 1988-09-15 | Behringwerke Ag | Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma |
US5043429B1 (en) * | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
US5097018A (en) * | 1988-05-12 | 1992-03-17 | University Of Southern California | Sequential heat treatment of blood-clotting factor products |
NL8701915A (nl) * | 1987-08-14 | 1989-03-01 | Waander Riethorst | Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren. |
DE3904354A1 (de) * | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
IT1306645B1 (it) | 1999-04-08 | 2001-10-02 | Challenger Gestao E Consultado | Struttura di sedia, poltroncina o simile ad assemblaggio facilitato. |
-
1988
- 1988-06-07 FR FR8807530A patent/FR2632309B1/fr not_active Expired - Lifetime
-
1989
- 1989-02-08 ES ES89400348T patent/ES2070919T5/es not_active Expired - Lifetime
- 1989-02-08 EP EP89400348A patent/EP0359593B2/fr not_active Expired - Lifetime
- 1989-02-08 DE DE68922358T patent/DE68922358T3/de not_active Expired - Lifetime
- 1989-02-08 US US07/460,972 patent/US5252709A/en not_active Expired - Lifetime
- 1989-02-08 KR KR1019900700239A patent/KR970010923B1/ko not_active IP Right Cessation
- 1989-02-08 JP JP1502342A patent/JP2805364B2/ja not_active Expired - Lifetime
- 1989-02-08 AT AT89400348T patent/ATE121750T1/de not_active IP Right Cessation
- 1989-02-08 AU AU30682/89A patent/AU622436B2/en not_active Expired
- 1989-02-08 WO PCT/FR1989/000050 patent/WO1989012065A1/fr active IP Right Grant
- 1989-02-08 DE DE198989400348T patent/DE359593T1/de active Pending
- 1989-02-14 CA CA000590961A patent/CA1340742C/fr not_active Expired - Lifetime
-
1990
- 1990-01-25 FI FI900397A patent/FI96210C/sv not_active IP Right Cessation
- 1990-02-05 NO NO900529A patent/NO177188C/no not_active IP Right Cessation
- 1990-02-06 DK DK199000299A patent/DK175322B1/da not_active IP Right Cessation
- 1990-02-06 UA UA4743107A patent/UA11061A/uk unknown
- 1990-02-06 RU SU904743107A patent/RU1837880C/ru active
-
1992
- 1992-03-03 AU AU1138392A patent/AU1138392A/en active Pending
- 1992-12-29 LT LTIP262A patent/LT3333B/lt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU1837880C (ru) | 1993-08-30 |
NO900529D0 (no) | 1990-02-05 |
UA11061A (uk) | 1996-12-25 |
KR900701823A (ko) | 1990-12-04 |
DE68922358D1 (de) | 1995-06-01 |
DK29990A (da) | 1990-03-28 |
AU3068289A (en) | 1990-01-05 |
FR2632309B1 (fr) | 1990-08-24 |
CA1340742C (fr) | 1999-09-14 |
ES2070919T5 (es) | 2004-07-16 |
DK175322B1 (da) | 2004-08-23 |
JPH03501974A (ja) | 1991-05-09 |
KR970010923B1 (ko) | 1997-07-02 |
FI96210C (sv) | 1996-05-27 |
EP0359593A1 (fr) | 1990-03-21 |
FI900397A0 (sv) | 1990-01-25 |
EP0359593B2 (fr) | 2004-01-07 |
DK29990D0 (da) | 1990-02-06 |
AU1138392A (en) | 1992-05-14 |
NO177188B (no) | 1995-04-24 |
LTIP262A (en) | 1994-10-25 |
JP2805364B2 (ja) | 1998-09-30 |
ES2070919T3 (es) | 1995-06-16 |
EP0359593B1 (fr) | 1995-04-26 |
NO177188C (no) | 1995-08-02 |
ATE121750T1 (de) | 1995-05-15 |
WO1989012065A1 (fr) | 1989-12-14 |
DE68922358T3 (de) | 2004-08-19 |
DE359593T1 (de) | 1990-09-27 |
US5252709A (en) | 1993-10-12 |
NO900529L (no) | 1990-04-06 |
LT3333B (en) | 1995-07-25 |
FR2632309A1 (fr) | 1989-12-08 |
AU622436B2 (en) | 1992-04-09 |
DE68922358T2 (de) | 1995-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI96210B (sv) | Kromatografisk avskiljning av plasmaproteiner | |
RU2088590C1 (ru) | Способ получения стандартизированного концентрата человеческого фактора виллебранда и концентрат, полученный этим способом | |
AU737986B2 (en) | Purification of von willebrand factor by cation exchange chromatography | |
JP5704918B2 (ja) | 第viii因子およびフォンビルブラント因子の精製方法 | |
FI95654B (sv) | Förfarande för framställning av ett koncentrat av ett komplex av blodkoagulationsfaktor VIII och von Willebrands faktor från helplasma | |
EP0468181A2 (en) | Process for the purification of factor VIII and factor VIII obtained by said process | |
HU214905B (hu) | Eljárás VIII. faktor izolálására | |
JP4660048B2 (ja) | 血漿プロテアーゼからのフィブリノゲンの分離 | |
CN106928344A (zh) | 用于从含有凝血因子的溶液中减少和/或除去FXI和FXIa的方法 | |
JPH03109400A (ja) | 鉄結合性蛋白質を分離、精製し、採取する方法 | |
MXPA02010017A (es) | Preparacion activa hemostaticamente, que contiene el factor de von willebrand y metodo para la produccion de la misma. | |
US20020019036A1 (en) | Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor | |
DK176139B1 (da) | Fremgangsmåde til separation af plasmaproteiner og plasmaproteinkoncentrater opnået ved fremgangsmåden | |
de Lille | Burnouf-Radosevich et a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB | Publication of examined application | ||
FG | Patent granted |
Owner name: CENTRE REGIONAL DE TRANSFUSION SANGUINE DE LILLE |
|
MA | Patent expired |